Abstract
The characterization of the biocompatibility of materials employed for medical diagnostic and therapeutic purposes is now well established as a fundamental requirement for such materials, as evidenced by the comprehensive and general guide published in the International Standard ISO-10993
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Duwe AK, Vas SI and Weatherhead JW. Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bactericidal activity in vitro. Infect Immun 1981; 33:130–5.
Holmes CJ. Biocompatibility of peritoneal dialysis solutions [editorial comment]. Peril Dial lnt 1993; 13:88–94.
Di Paolo N, Garosi G, Monaci G and Brardi S. Biocompatibility of peritoneal dialysis treatment. Nephrol Dialysis Transplant 1997; 12:78–83.
Breborowicz A, Bolaskas E, Oreopoulos D et al. A new approach in the study of dialysis fluid toxicity on the peritoneal membrane. Perit Dial Int 1991; 11:A29.
Topley N. What is the ideal technique for testing the biocompatibility of peritoneal dialysis solutions. Perit Dial Int 1995; 15:205–9.
Anderson B and Amirault H. Important variables in granulocyte chemiluminescence. Proceedings of the society for experimental biology and medicine 1979; 162:139–45.
Schmidt R, Chung L, Andrews A and Turner T. Toxicity of L-ascorbic acid to L929 fibroblast cultures: relevance to biocompatibility testing of materials for use in wound management. J Biomedl Mat Res 1993; 27:521–30.
Breborowicz A, Bolaskas E, Oreopoulos D et al. Co-culture of peritoneal dialysate cells with mesothelial cells and fibroblasts. Perit Dial Int 1991; 11:A31.
Gotloib L, Shostak A and Wajsbrot V. Detrimental effects of peritoneal dialysis solutions upon in vivo and in situ exposed mesothelium. Perit Dial Int 1997; 17:13–16.
Ho-dac-Pannekeet M, Hiralall J, Struijk D and Krediet R. Longitudinal follow-up of CA 125 in peritoneal effluent. Kidney Int 1997; 51:888–93.
Lai K, Lai K, Szeto C, Ho K, Poon P, Lam C et al. Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: their relationship with transport parameters. Am J Kidney Dis 1997; 29:669–705.
Fischereder M, Luckow B, Sitter T, Schroppel B, Banas B and Schlondorff D. Immortalization and characterization of human peritoneal mesothelial cells. Kidney Int 1997; 51:2006–12.
Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182 6.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Kluwer Academic Publishers
About this chapter
Cite this chapter
Holmes, C.J. (1999). Criteria for biocompatibility testing of peritoneal dialysis solutions. In: Henderson, L.W., Thuma, R.S. (eds) Quality Assurance in Dialysis. Developments in Nephrology, vol 39. Springer, Dordrecht. https://doi.org/10.1007/978-0-585-28312-8_23
Download citation
DOI: https://doi.org/10.1007/978-0-585-28312-8_23
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-5281-5
Online ISBN: 978-0-585-28312-8
eBook Packages: Springer Book Archive